
Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>



































| Items | Size (2mg) | Size(2mg X 5) |
| Particle size | 2 μm | 2 μm |
| Physical appearance | Powder mixture | Powder mixture |
| Amount of Coupled Protein | ≈332.9 pmol (31μg) FAP protein/mg beads | ≈332.9 pmol (31μg) FAP protein/mg beads |
| Capacity | >133.3 pmol (20μg) Anti-FAP Ab/mg beads | >133.3 pmol (20μg) Anti-FAP Ab/mg beads |
| Formulation | PBS, pH7.4,with 10% Trehalose | PBS, pH7.4,with 10% Trehalose |
| Reconstitution | 2mL ultrapure water (1 mg beads/mL) | 2mL ultrapure water (1 mg beads/mL) |
See Certificate of Analysis (CoA) for detailed instruction.
Please contact us for detailed information.
Contact us for customized product form or formulation.

Immobilized 33.8μg Biotinylated Human FAP protein to 1mg Beads can bind the Anti-FAP Antibody with an EC50 0.13 μg/mL (QC tested).
Emerging VoCs, Omicron, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
CD3 proteins and a collection of for bispecific antibody development which are of high specificity and bioactivities and suitable for immunization, antibody screening.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
The MABSOL biotinylated protein collection includes more than a hundred commonly studied drug targets and biomarker proteins.
Comprehensive cytokines including IL families, growth factors, chemokines, TNFs, etc. These products are HEK293 expressed and nearly in authentic structure, high purity and bioactivity, cell based assay/SPR/BLI verified.
To support preclinical/clinical immunogenicity and PK analysis, ACROBiosystems has developed a series of high-affinity anti-idiotypic antibodies. Our pipeline covers five hot targets including adalimum*b, rituxim*b, cetuxim*b, trastuzum*b, and bevacizum*b.
| English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|
| English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| FAP-DR5 | RG-7386; RO-6874813 | Millennium Pharmaceuticals Inc, F. Hoffmann-La Roche Ltd | Details | ||
| Simlukafusp alfa | FAP-IL2v; RG-7461; aFAP-IL2v; RO-6874281; FAP-IL2v FP | F. Hoffmann-La Roche Ltd | Details | ||
| 177Lu-FAP-2286 | 177Lu-FAP-2286 | Phase 2 Clinical | 3B Pharmaceuticals GmbH | Solid tumours | Details |
| 68Ga-FAP-2286 | 68Ga-FAP-2286; 68-Ga-FAP-2286 | Phase 2 Clinical | 3B Pharmaceuticals GmbH | Solid tumours; Neoplasm Metastasis | Details |
| Nectin4/FAP-targeted CAR-T cell therapy (The Sixth Affiliated Hospital of Wenzhou Medical University) | Phase 1 Clinical | Wenzhou Medical University, The Sixth Affiliated Hospital Of Wenzhou Medical University | Solid tumours | Details | |
| OMTX-705 | OMTX-705 | Phase 1 Clinical | Oncomatryx Biopharma Sl | Solid tumours | Details |
| RO-7300490 | RO-7300490; RG-6189 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Solid tumours; Neoplasms | Details |
| Talabostat | PT-100; BXCL-701 | Phase 2 Clinical | Midatech Pharma Plc, Bioxcel Therapeutics Inc | Neuroblastoma; Melanoma; Leukemia, Lymphocytic, Chronic, B-Cell; Adenocarcinoma; Neoplasms, Germ Cell and Embryonal; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Carcinoma, Pancreatic Ductal; Lung Neoplasms; Carcinoma, Small Cell; Brain Neoplasms; Solid tumours; Sarcoma; Prostatic Neoplasms; Central Nervous System Neoplasms; Neuroendocrine Tumors; Skin Neoplasms; Pancreatic Neoplasms; Kidney Neoplasms; Ovarian Neoplasms; Liver Neoplasms | Details |
| 177Lu-PNT6555(Point Biopharma) | PNT-6555 | Phase 1 Clinical | Point Biopharma Inc | Solid tumours; Esophageal Neoplasms; Sarcoma; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Melanoma | Details |
| [18F]FAPI-74 | FAPI-74; [18F]FAPI-74 | Phase 2 Clinical | Sofie | Biliary Tract Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Colorectal Neoplasms; Carcinoma, Hepatocellular | Details |
| MP-0310 | MP-0310; AMG-506 | Phase 1 Clinical | Molecular Partners Ag, Amgen Inc | Solid tumours | Details |
This web search service is supported by Google Inc.




